# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis

> **NCT07024602** · PHASE1 · RECRUITING · sponsor: **Ascletis Pharma (China) Co., Limited** · enrollment: 94 (estimated)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** ASC50 tablets or matching placebo

## Key facts

- **NCT ID:** NCT07024602
- **Lead sponsor:** Ascletis Pharma (China) Co., Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2025-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07024602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07024602, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07024602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*